Pathways-to-Care Analysis of Non-Hodgkin Lymphoma in Ethiopia: A Mixed-Methods Study.
환자-대조
2/5 보강
OpenAlex 토픽 ·
Global Cancer Incidence and Screening
Advances in Oncology and Radiotherapy
Acute Lymphoblastic Leukemia research
[PURPOSE] Detailed understanding of patient pathways and barriers to care is essential in devising context-appropriate cancer care strategies in low-income countries.
- 표본수 (n) 174
- 95% CI 1.3 to 25
- 연구 설계 case-control
APA
Obsie T. Baissa, Fozia Abdela, et al. (2026). Pathways-to-Care Analysis of Non-Hodgkin Lymphoma in Ethiopia: A Mixed-Methods Study.. JCO global oncology, 12(4), e2500589. https://doi.org/10.1200/GO-25-00589
MLA
Obsie T. Baissa, et al.. "Pathways-to-Care Analysis of Non-Hodgkin Lymphoma in Ethiopia: A Mixed-Methods Study.." JCO global oncology, vol. 12, no. 4, 2026, pp. e2500589.
PMID
42024844 ↗
Abstract 한글 요약
[PURPOSE] Detailed understanding of patient pathways and barriers to care is essential in devising context-appropriate cancer care strategies in low-income countries.
[METHODS] We conducted a mixed-methods study nested within a case-control study among patients newly diagnosed with non-Hodgkin lymphoma (NHL; N = 174) in two referral centers in Ethiopia. Structured interviews and chart reviews were followed by in-depth interviews in a subsample (n = 17). Care intervals were defined via Andersen's model and determinants of delay were assessed with logistic regression; thematic analysis was used for qualitative data.
[RESULTS] Mean age at diagnosis was 51.4 years (standard deviation, 13.70); 67% had advanced disease. Median patient, primary health care, and tertiary care intervals were 86.5, 15, and 47 days, respectively. Median diagnostic interval was 66.5 days. Delay was associated with lower education (adjusted odds ratio [AOR], 6.3 [95% CI, 1.3 to 25]) and indolent lymphoma (AOR, 2.9 [95% CI, 1.3 to 6.2]). Treatment abandonment was 16.8%, and 9.8% were dead at 3 months. Loss to follow-up (21.8%) was associated with study site (AOR, 6.1 [95% CI, 2.6 to 29.9]) and diagnostic delay >30 days (AOR, 4.8 [95% CI, 1.6 to 14.3]). Qualitative analysis identified symptom misappraisal, misdiagnosis, long waits, high out-of-pocket costs, and long travel distances.
[CONCLUSION] Delays across Ethiopia's NHL care continuum reflect low health literacy, diagnostic bottlenecks, and persistent financial barriers.
[METHODS] We conducted a mixed-methods study nested within a case-control study among patients newly diagnosed with non-Hodgkin lymphoma (NHL; N = 174) in two referral centers in Ethiopia. Structured interviews and chart reviews were followed by in-depth interviews in a subsample (n = 17). Care intervals were defined via Andersen's model and determinants of delay were assessed with logistic regression; thematic analysis was used for qualitative data.
[RESULTS] Mean age at diagnosis was 51.4 years (standard deviation, 13.70); 67% had advanced disease. Median patient, primary health care, and tertiary care intervals were 86.5, 15, and 47 days, respectively. Median diagnostic interval was 66.5 days. Delay was associated with lower education (adjusted odds ratio [AOR], 6.3 [95% CI, 1.3 to 25]) and indolent lymphoma (AOR, 2.9 [95% CI, 1.3 to 6.2]). Treatment abandonment was 16.8%, and 9.8% were dead at 3 months. Loss to follow-up (21.8%) was associated with study site (AOR, 6.1 [95% CI, 2.6 to 29.9]) and diagnostic delay >30 days (AOR, 4.8 [95% CI, 1.6 to 14.3]). Qualitative analysis identified symptom misappraisal, misdiagnosis, long waits, high out-of-pocket costs, and long travel distances.
[CONCLUSION] Delays across Ethiopia's NHL care continuum reflect low health literacy, diagnostic bottlenecks, and persistent financial barriers.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.